Covid-19 vaccine after collecting safety data to submit to US regulators, the company's CEO said on Tuesday, according to a report.
Last week, Pfizer and its partner BioNTech SE reported that an interim analysis showed their experimental vaccine was more than 90% effective in preventing symptomatic cases of Covid-19."We are very close to submitting for an emergency use authorization," Albert Bourla told medical news site Stat.